Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress
Provided By GlobeNewswire
Last update: May 12, 2025
NORCROSS, Ga., May 12, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, presented a late-breaking oral presentation of the NAVIGATE study analysis at the EASL 2025 Congress, on May 10, 2025, in Amsterdam, Netherlands. The NAVIGATE study evaluated belapectin, a galectin-3 inhibitor, in patients with MASH cirrhosis and portal hypertension.
Read more at globenewswire.com3.29
+0.9 (+37.66%)
Find more stocks in the Stock Screener
GALT Latest News and Analysis
3 days ago - ChartmillThese stocks are moving in today's sessionKeep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.
3 days ago - ChartmillWhich stocks are moving on Tuesday?Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.
